Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(01): 73-77
DOI: 10.4103/0971-5851.203495
Practitioner Section

Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation

Milena Peitl
Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
,
Sven Seiwerth
Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
,
Martina Bašić-Koretić
Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
,
Fedor Šantek
Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) is generally an understudied disease, largely because most molecular and clinical studies of mesothelioma have been conducted in patients with the more common malignant pleural mesothelioma. We present the case of a 45-year-old male that initially presented with abdominal discomfort and ascites. Diagnostic workup revealed advanced DMPM. Bimodal treatment was stared with cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy procedure, followed by pemetrexed systemic monotherapy. After the disease progression, and because of a very good previous treatment response to pemetrexed, we decided to rechallenge systemic pemetrexed, along with the introduction of cisplatin. Although the intent behind systemic treatment was atfirst solely palliative, overall survival after the initial diagnosis was 50 months. Treatment based on rechallenging pemetrexed with or without cisplatin in patients with advanced DMPM can result in a quite satisfactory disease control and symptom management.

Keywords

Diffuse malignant peritoneal mesothelioma - pemetrexed rechallenging - treatment options


Publication History

Article published online:
06 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Chua TC, Yan TD, Morris DL. Surgical biology for the clinician: Peritoneal mesothelioma: Current understanding and management. Can J Surg 2009;52:59-64.
  • 2 Alexander HR. Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging. In: Tannabe KK, editor. UpToDate, Waltham, MA. Available from: https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-epidemiology-risk-factors-clinical-presentation-diagnosis-and-staging?source=search_result&search=Alexander%20HR.%20Malignant%20peritoneal%20mesothelioma:%20Epidemiology,%20risk%20factors,%20clinical%20presentation,%20diagnosis,%20and%20staging.%20In:%20Tannabe%20KK,%20editor.%20UpToDate,%20Waltham,%20MA&selectedTitle=2~150. [Last accessed on 2016 Jun 13].
  • 3 Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma – An update on treatment. Cancer Treat Rev 2012;38:605-12.
  • 4 Boffetta P. Epidemiology of peritoneal mesothelioma: A review. Ann Oncol 2007;18:985-90.
  • 5 Kindler HL. Malignant peritoneal mesothelioma. In: Tannabe KK, editor. UpToDate. Waltham, MA. Available from: https://www.uptodate.com/contents/malignant-peritoneal-mesothelioma-treatment. [Last accessed on 2016 Jun 13].
  • 6 Saraya T, Yokoyama T, Ishii H, Tanaka Y, Tsujimoto N, Ogawa Y, et al. A case of malignant peritoneal mesothelioma revealed with limitation of PET-CT in the diagnosis of thoracic metastasis. J Thorac Dis 2013;5:E11-6.
  • 7 Samedi V, White S, Zimarowski MJ, Harris A, Saffitz J, Wang HH. Metastatic peritoneal mesothelioma in the setting of recurrent ascites: A case report. Diagn Cytopathol 2010;38:675-81.
  • 8 Ito H, Imada T, Kondo J, Amano T, Maehara T, Rino Y, et al. A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy. Jpn J Clin Oncol 1998;28:145-8.
  • 9 Kliem V, Maschek H, Bleck J, Schmidt FW. Malignant peritoneal mesothelioma with unusual and extensive metastasis. Dtsch Med Wochenschr 1991;116:1468-72.
  • 10 Lugaresi ML, Mattioli S, Pilotti V, Guernelli N. Pulmonary metastasis of malignant peritoneal mesothelioma. Review of the literature and a case report. Minerva Chir 2000;55:357-61.
  • 11 Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, et al. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: Retrospective analysis of six cases. Anticancer Res 2014;34:215-20.
  • 12 Tan A, Cohen P, Raoofi M, Tan J, Mesbah Ardakani N, Sterrett G. Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear. Acta Cytol 2015;59:498-504.
  • 13 Pavlisko EN, Roggli VL. Sarcomatoid peritoneal mesothelioma: Clinicopathologic correlation of 13 cases. Am J Surg Pathol 2015;39:1568-75.
  • 14 Frontario SC, Loveitt A, Goldenberg-Sandau A, Liu J, Roy D, Cohen LW. Primary peritoneal mesothelioma resulting in small bowel obstruction: A case report and review of literature. Am J Case Rep 2015;16:496-500.
  • 15 Zha BS, Flanagan M, Coulson C, Garvin KW. Difficult to identify: Malignant primary peritoneal mesothelioma. Am J Med 2015;128:1191-4.
  • 16 Rupert K, Treška V. Malignant mesothelioma in the peritoneal cavity – A case report. Rozhl Chir 2015;94:166-9.
  • 17 Haberman A. Unusual appearance of malignant peritoneal mesothelioma. J Comput Assist Tomogr 2015;39:419-21.
  • 18 Kobayashi M, Moriwaki T, Ochi D, Saito R, Kobayashi K, Sugaya A, et al. A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin. Gan To Kagaku Ryoho 2014;41:361-4.
  • 19 Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: A review. MedGenMed 2007;9:32.
  • 20 Kikuchi Y, Watanabe T, Igarashi Y, Sumino Y, Tsuboi K. The chemotherapy of peritoneal malignant mesothelioma. Gan To Kagaku Ryoho 2012;39:718-21.
  • 21 Gilani SN, Gridley R, Searle G, Jegannathen A. Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review. BMJ Case Rep 2013;3. Available from: http://www.casereports.bmj.com/content/2013/bcr-2012-007786.long. [Last cited on 2016 Sep 12].
  • 22 Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003;21:4560-7.